What is HC Wainwright’s Estimate for CNTB FY2028 Earnings?

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) – Research analysts at HC Wainwright raised their FY2028 earnings per share (EPS) estimates for shares of Connect Biopharma in a note issued to investors on Monday, January 26th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($0.79) per share for the year, up from their previous forecast of ($0.80). The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.22) per share.

Connect Biopharma (NASDAQ:CNTB) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.07).

Several other research firms have also recently weighed in on CNTB. Lake Street Capital began coverage on shares of Connect Biopharma in a research note on Monday, December 1st. They issued a “buy” rating and a $9.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Connect Biopharma in a research report on Wednesday, January 21st. Wall Street Zen raised Connect Biopharma to a “hold” rating in a research note on Saturday, December 20th. Finally, BTIG Research restated a “buy” rating and issued a $10.00 target price on shares of Connect Biopharma in a research report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.67.

Connect Biopharma Price Performance

Connect Biopharma stock opened at $2.55 on Wednesday. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $2.51 and a 200 day moving average price of $2.07. Connect Biopharma has a 12-month low of $0.51 and a 12-month high of $3.28. The stock has a market cap of $142.55 million, a P/E ratio of -3.49 and a beta of -0.19.

Institutional Investors Weigh In On Connect Biopharma

Several institutional investors and hedge funds have recently modified their holdings of the company. AlphaCore Capital LLC purchased a new position in Connect Biopharma during the 2nd quarter valued at about $78,000. Koa Wealth Management LLC purchased a new stake in Connect Biopharma during the second quarter worth about $49,000. Finally, XTX Topco Ltd acquired a new stake in shares of Connect Biopharma during the second quarter worth about $29,000. Hedge funds and other institutional investors own 58.72% of the company’s stock.

About Connect Biopharma

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.